BACKGROUND: Clinical trials in pediatric acute myeloid leukemia (AML) determine induction regimen standards. However, these studies lack the data necessary to evaluate mortality trends over time and differences in resource utilization between induction regimens. Moreover, these trials likely underreport the clinical toxicities experienced by patients. METHODS: The Pediatric Health Information System database was used to identify children treated for presumed de novo AML between 1999 and 2010. Induction mortality, risk factors for induction mortality, and resource utilization by induction regimen were estimated using standard frequentist statistics, logistic regression, and Poisson regression, respectively. RESULTS: A total of 1686 patients were identified with an overall induction case fatality rate of 5.4% that decreased from 9.8% in 2003 to 2.1% in 2009 (P = .0023). The case fatality rate was 9.0% in the intensively timed DCTER (dexamethasone, cytarabine, thioguanine, etoposide, and rubidomycin [daunomycin]/idarubicin) induction and 3.8% for ADE (cytarabine, daunomycin, and etoposide) induction (adjusted odds ratio = 2.2, 95% confidence interval = 1.1-4.5). Patients treated with intensively timed DCTER regimens had significantly greater antibiotic, red cell/platelet transfusion, analgesic, vasopressor, renal replacement therapy, and radiographic resource utilization than patients treated with ADE regimens. Resource utilization was substantially higher than reported in published pediatric AML clinical trials. CONCLUSIONS: Induction mortality for children with AML decreased significantly as ADE use increased. In addition to higher associated mortality, intensively timed DCTER regimens had a correspondingly higher use of health care resources. Using resource utilization data as a proxy for adverse events, adverse event rates reported on clinical trials substantially underestimated the clinical toxicities of all pediatric AML induction regimens.
BACKGROUND: Clinical trials in pediatric acute myeloid leukemia (AML) determine induction regimen standards. However, these studies lack the data necessary to evaluate mortality trends over time and differences in resource utilization between induction regimens. Moreover, these trials likely underreport the clinical toxicities experienced by patients. METHODS: The Pediatric Health Information System database was used to identify children treated for presumed de novo AML between 1999 and 2010. Induction mortality, risk factors for induction mortality, and resource utilization by induction regimen were estimated using standard frequentist statistics, logistic regression, and Poisson regression, respectively. RESULTS: A total of 1686 patients were identified with an overall induction case fatality rate of 5.4% that decreased from 9.8% in 2003 to 2.1% in 2009 (P = .0023). The case fatality rate was 9.0% in the intensively timed DCTER (dexamethasone, cytarabine, thioguanine, etoposide, and rubidomycin [daunomycin]/idarubicin) induction and 3.8% for ADE (cytarabine, daunomycin, and etoposide) induction (adjusted odds ratio = 2.2, 95% confidence interval = 1.1-4.5). Patients treated with intensively timed DCTER regimens had significantly greater antibiotic, red cell/platelet transfusion, analgesic, vasopressor, renal replacement therapy, and radiographic resource utilization than patients treated with ADE regimens. Resource utilization was substantially higher than reported in published pediatric AML clinical trials. CONCLUSIONS: Induction mortality for children with AML decreased significantly as ADE use increased. In addition to higher associated mortality, intensively timed DCTER regimens had a correspondingly higher use of health care resources. Using resource utilization data as a proxy for adverse events, adverse event rates reported on clinical trials substantially underestimated the clinical toxicities of all pediatric AML induction regimens.
Authors: Scott P Narus; Rajendu Srivastava; Ramkiran Gouripeddi; Oren E Livne; Peter Mo; Jonathan P Bickel; David de Regt; Joseph W Hales; Eric Kirkendall; Richard L Stepanek; Jamie Toth; Ron Keren Journal: AMIA Annu Symp Proc Date: 2011-10-22
Authors: Jeffrey S Gerber; Jason G Newland; Susan E Coffin; Matt Hall; Cary Thurm; Priya A Prasad; Chris Feudtner; Theoklis E Zaoutis Journal: Pediatrics Date: 2010-11-15 Impact factor: 7.124
Authors: Todd M Cooper; Janet Franklin; Robert B Gerbing; Todd A Alonzo; Craig Hurwitz; Susana C Raimondi; Betsy Hirsch; Franklin O Smith; Prasad Mathew; Robert J Arceci; James Feusner; Robert Iannone; Robert S Lavey; Soheil Meshinchi; Alan Gamis Journal: Cancer Date: 2011-07-15 Impact factor: 6.860
Authors: R Aplenc; B T Fisher; Y S Huang; Y Li; T A Alonzo; R B Gerbing; M Hall; D Bertoch; R Keren; A E Seif; L Sung; P C Adamson; A Gamis Journal: Pharmacoepidemiol Drug Saf Date: 2012-05 Impact factor: 2.890
Authors: Brian T Fisher; Tracey Harris; Kari Torp; Alix E Seif; Ami Shah; Yuan-Shung V Huang; L Charles Bailey; Leslie S Kersun; Anne F Reilly; Susan R Rheingold; Dana Walker; Yimei Li; Richard Aplenc Journal: Med Care Date: 2014-01 Impact factor: 2.983
Authors: Ching-Hon Pui; Deqing Pei; Alberto S Pappo; Scott C Howard; Cheng Cheng; John T Sandlund; Wayne L Furman; Raul C Ribeiro; Sheri L Spunt; Jeffrey E Rubnitz; Sima Jeha; Melissa M Hudson; Larry E Kun; Thomas E Merchant; Mehmet Kocak; Alberto Broniscer; Monika L Metzger; James R Downing; Wing Leung; William E Evans; Amar Gajjar Journal: J Clin Oncol Date: 2012-04-30 Impact factor: 44.544
Authors: Marko Kavcic; Brian T Fisher; Kari Torp; Yimei Li; Yuan-Shung Huang; Alix E Seif; Marijana Vujkovic; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2012-11-28 Impact factor: 3.167
Authors: Brenda E S Gibson; David K H Webb; Andrew J Howman; Siebold S N De Graaf; Christine J Harrison; Keith Wheatley Journal: Br J Haematol Date: 2011-09-09 Impact factor: 6.998
Authors: Yimei Li; Joanna G Newton; Kelly D Getz; Yuan-Shung Huang; Alix E Seif; Brian T Fisher; Richard Aplenc; Lena E Winestone Journal: Pediatr Blood Cancer Date: 2018-12-26 Impact factor: 3.167
Authors: Elizabeth G Salazar; Yimei Li; Brian T Fisher; Susan R Rheingold; Julie Fitzgerald; Alix E Seif; Yuan-Shung Huang; Rochelle Bagatell; Richard Aplenc Journal: Br J Haematol Date: 2016-05-10 Impact factor: 6.998
Authors: Julie C Fitzgerald; Yimei Li; Brian T Fisher; Yuan-Shung Huang; Tamara P Miller; Rochelle Bagatell; Alix E Seif; Richard Aplenc; Neal J Thomas Journal: Pediatr Crit Care Med Date: 2018-06 Impact factor: 3.624
Authors: Lena E Winestone; Kelly D Getz; Tamara P Miller; Jennifer J Wilkes; Leah Sack; Yimei Li; Yuan-Shung Huang; Alix E Seif; Rochelle Bagatell; Brian T Fisher; Andrew J Epstein; Richard Aplenc Journal: Am J Hematol Date: 2016-12-07 Impact factor: 10.047
Authors: Tamara P Miller; Andrea B Troxel; Yimei Li; Yuan-Shung Huang; Todd A Alonzo; Robert B Gerbing; Matt Hall; Kari Torp; Brian T Fisher; Rochelle Bagatell; Alix E Seif; Lillian Sung; Alan Gamis; David Rubin; Selina Luger; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2015-03-11 Impact factor: 3.167
Authors: Shannon L Maude; Julie C Fitzgerald; Brian T Fisher; Yimei Li; Yuan-Shung Huang; Kari Torp; Alix E Seif; Marko Kavcic; Dana M Walker; Kateri H Leckerman; Todd J Kilbaugh; Susan R Rheingold; Lillian Sung; Theoklis E Zaoutis; Robert A Berg; Vinay M Nadkarni; Neal J Thomas; Richard Aplenc Journal: Pediatr Crit Care Med Date: 2014-02 Impact factor: 3.624
Authors: Ami V Desai; Alix E Seif; Yimei Li; Kelly Getz; Brian T Fisher; Vera Huang; Adjoa Mante; Richard Aplenc; Rochelle Bagatell Journal: Pediatr Blood Cancer Date: 2016-01-21 Impact factor: 3.167
Authors: Mallorie B Heneghan; Susan R Rheingold; Yimei Li; Alix E Seif; Yuan-Shung Huang; Lisa McLeod; Lawrence Wells; Brian T Fisher; Richard Aplenc Journal: Clin Lymphoma Myeloma Leuk Date: 2016-01-04
Authors: Eman Biltaji; Elena Y Enioutina; Venkata Yellepeddi; Joseph E Rower; Catherine M T Sherwin; Robert M Ward; Richard S Lemons; Jonathan E Constance Journal: Leuk Lymphoma Date: 2020-04-07